However, due to the rapid tumour targeting and fast internalization of low molecular weight PSMA ligands, the circulation time is much shorter than that of full-length antibodies evaluated for radioimmunotherapy [8, 25, 26]. The gene discussed is FOLH1; the disease is neoplasm.